变应性鼻炎免疫治疗共识及相关进展

doi:10.6040/j.issn.1673-3770.0.2016.278

摘要/Abstract

关键词: 变应性鼻炎, 免疫治疗, 变应原

Key words: Allergic rhinitis, Allergens, Immunotherapy

中图分类号:

R765.21

李勇. 变应性鼻炎免疫治疗共识及相关进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 15-21.

LI Yong. Progress of immunotherapy for allergic rhinitis.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 15-21.

[1] Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy [J]. J Allergy Clin Immunol, 2015, 136(3): 556-568.
[2] Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper [J]. Allergy, 2014, 69(7): 854-867.
[3] 中国过敏性鼻炎研究协作组. 过敏性鼻炎皮下免疫治疗专家共识2015 [J]. 中国耳鼻咽喉头颈外科, 2015, 22(8): 379-404.
[4] Calderon M, Cardona V, Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions [J]. Allergy, 2012, 67(4): 462-476.
[5] CMS update: desensitizing vaccines [J]. Br Med J, 1986, 293(6552): 984.
[6] 宋薇薇, 林小平, 柴若楠, 等. 东北地区夏秋季花粉症患者变应原特异性免疫治疗的长期疗效 [J]. 中华临床免疫和变态反应杂志, 2012, 6(4): 266-271. SONG Weiwei, LIN Xiaoping, CHAI Ruonan, et al. Long-term efficacy of allergen specific immunotherapy for pollinosis patients in northeast china [J]. Chin J Allergy Clin Immunol, 2012, 6(4): 266-271.
[7] 关凯, 魏庆宇, 尹佳. 葎草花粉变应原免疫治疗疗效和安全性评估 [J]. 中华临床免疫和变态反应杂志, 2012, 6(4): 279-284. GUAN Kai, WEI Qingyu, YIN Jia. Efficacy and safety of specific immunotherapy with Humulus Pollen extract[J]. Chin J Allergy Clin Immunol, 2012, 6(4): 279-284.
[8] 叶世泰, 李美琏, 何海娟, 等. 过敏性鼻炎患者在特异性脱敏治疗中血清IgE的动态观察 [J]. 中华耳鼻咽喉科杂志, 1982, 17(2): 147-148.
[9] 文昭明,叶世泰. 免疫疗法致不良反应的临床观察——附29例报告[J]. 中华微生物学和免疫学杂志, 2001(S2):68-71.
[10] 张罗, 韩德民. 变应性鼻炎的变应原特异性皮下免疫治疗 [J]. 中华耳鼻咽喉头颈外科杂志, 2007, 42(9): 711-716. ZHANG Luo, HAN Demin. Allergen-specific subcutaneous immunotherapy for allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2007, 42(9):711-716.
[11] 尹佳. 北京协和医院变应原制剂应用指南 [M]. 北京: 中国协和医科大学出版社, 2014.
[12] Canonica G W, Baena-Cagnani C E, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization(WAO)taskforce [J]. Allergy, 2007, 62(3): 317-324.
[13] Rosner-Friese K, Kaul S, Vieths S, et al. Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs [J]. J Allergy Clin Immunol, 2015, 135(3): 636-643.
[14] Brozek J L, Bousquet J, Baena-Cagnani C E, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010,126(3):466-476.
[15] Canonica G W, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update[J]. World Allergy Organ J, 2014,7(1):6.
[16] Wilson D R, Lima M T, Durham S R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis[J]. Allergy, 2005,60(1):4-12.
[17] Pitsios C, Demoly P, Bilò M B, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper [J]. Allergy, 2015, 70(8): 897-909.
[18] Casale T B, Stokes J R. Immunotherapy: what lies beyond [J]. J Allergy Clin Immunol, 2014, 133(3): 612-619: quiz 620.
[19] von Moos S, Johansen P, Tay F, et al. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy [J]. J Allergy Clin Immunol, 2014, 134(4): 965-967.e964.
[20] Tabar A I, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus[J]. J Allergy Clin Immunol, 2005, 116(1): 109-118.
[21] Temino V M, Wu P, Konig J, et al. Safety of multiple aeroallergen rush immunotherapy using a modified schedule [J]. Allergy Asthma Proc, 2013, 34(3): 255-260.
[22] Rieker-Schwienbacher J, Nell M J, Diamant Z, et al. Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients [J]. Clin Transl Allergy, 2013, 3(1): 16.
[23] Durham S R, Walker S M, Varga E M, et al. Long-term clinical efficacy of grass-pollen immunotherapy [J]. N Engl J Med, 1999, 341(7): 468-475.
[24] Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation, Allergy, 1996, 51(6): 430-433.
[25] Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study [J]. J Allergy Clin Immunol, 2010, 126(5): 969-975.
[26] Calderon M A, Cox L, Casale T B, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence [J]. J Allergy Clin Immunol, 2012, 129(4): 929-934.
[27] Calderon M A, Cox L S. Monoallergen sublingual immunotherapy versus multiallergen subcutaneous immunotherapy for allergic respiratory diseases: a debate during the AAAAI 2013 Annual Meeting in San Antonio, Texas [J]. J Allergy Clin Immunol Pract, 2014, 2(2): 136-143.
[28] Nelson H S. Multiallergen immunotherapy for allergic rhinitis and asthma [J]. J Allergy Clin Immunol, 2009, 123(4): 763-769.
[29] Amar S M, Harbeck R J, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract [J]. J Allergy Clin Immunol, 2009, 124(1): 150-156.e151-155.
[30] Canonica G W, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009 [J]. Allergy, 2009, 64(Suppl 91): 1-59.
[31] Kim J M, Lin S Y, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review [J]. Pediatrics, 2013, 131(6):1155-1167.
[32] Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update [J]. J Allergy Clin Immunol, 2011, 127(Suppl 1): S1-55.
[33] Cox L S, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review [J]. J Allergy Clin Immunol, 2006, 117(5): 1021-1035.
[34] Makatsori M, Scadding G W, Lombardo C, et al. Dropouts in sublingual allergen immunotherapy trials-a systematic review [J]. Allergy, 2014, 69(5): 571-580.
[35] Passalacqua G, Baena-Cagnani C E, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language [J]. J Allergy Clin Immunol, 2013, 132(1): 93-98.
[36] Cox L, Larenas-Linnemann D, Lockey R F, et al. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System [J]. J Allergy Clin Immunol, 2010, 125(3): 569-574, 574.e561-574.e567.
[37] Coop C A, Tankersley M S. Patient perceptions regarding local reactions from allergen immunotherapy injections [J]. Ann Allergy Asthma Immunol, 2008, 101(1): 96-100.
[38] Kelso J M. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction [J]. Ann Allergy Asthma Immunol, 2004, 92(2): 225-227.
[39] Tankersley M S, Butler K K, Butler W K, et al. Local reactions during allergen immunotherapy do not require dose adjustment [J]. J Allergy Clin Immunol, 2000, 106(5): 840-843.
[40] Roy S R, Sigmon J R, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy [J]. Ann Allergy Asthma Immunol, 2007, 99(1): 82-86.
[41] Epstein T G, Liss G M, Murphy-Berendts K, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions [J]. J Allergy Clin Immunol Pract, 2014, 2(2): 161-167.
[42] Bernstein D I, Epstein T, Murphy-Berendts K, et al. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study [J]. Ann Allergy Asthma Immunol, 2010, 104(6): 530-535.
[43] Tinkelman D G, Cole W Q, 3rd Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions [J]. J Allergy Clin Immunol, 1995, 95(1 Pt 1): 8-14.
[44] Cox L, Aaronson D, Casale T B, et al. Allergy immunotherapy safety: location matters [J]. J Allergy Clin Immunol Pract, 2013, 1(5): 455-457.
[45] Calderon M A, Simons F E, Malling H J, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile [J]. Allergy, 2012, 67(3): 302-311.
[46] de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet [J]. Allergy, 2009, 64(6): 963-964.
[47] Miehlke S, Alpan O, Schroder S, et al. Induction of eosinophilic esophagitis by sublingual pollen immunotherapy [J]. Case Rep Gastroenterol, 2013, 7(3): 363-368.
[48] HollisterStier Allergy, Allergenic extracts in bulk vial. Available at: http://www.hsallergy.com/products_ordering/product_inserts.aspx. In, May 11, 2013.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed